1 min read
Add as a preferred source on GoogleGenmab and Incyte Plan Phase 1/2 Trial for KRAS-Mutated Metastatic Colorectal Cancer
The study will combine petosemtamab and INCB161734 with chemotherapy as a potential first-line treatment.
Genmab A/S and Incyte will test a drug combination in a Phase 1/2 study for metastatic colorectal cancer with a KRAS G12D mutation, evaluating it as a potential first-line treatment.
The combination will include petosemtamab, Genmab’s investigational drug, and INCB161734, Incyte’s investigational drug, alongside chemotherapy.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.